Objective This study seeks to assess behavioural risk in people with HIV receiving antiretroviral (ARV) therapy in Thailand and Cambodia and to test a strategy to modify these behaviours and consequently reduce the rate of HIV transmission.
Specific Aims 1. Measure beliefs and perceptions about ARV therapy, particularly as they relate to HIV transmission 2. Identify characteristics at an individual, family, community and contextual level that predict sexual and injecting risk behaviour and behaviour change in people with HIV infection taking ARV therapy, and which may be modifiable through a counselling intervention 3. Develop and test a counselling-based intervention to reduce the level of risk behaviour among people with HIV infection taking ARV therapy. METHODS The project will be conducted in two stages over five years. The first stage will collect data on beliefs and perceptions, risk behaviours and the factors that predict risk behaviour. Stage two will use these data to develop a risk reduction intervention and test it for long term effectiveness. EXPECTED OUTCOMES 1. Identification of an effective means of modifying high risk behaviours in people taking ARV therapy in a developing country setting. 2. Increased ability to provide appropriate psychosocial support to infected persons and affected communities. 3. Increased capacity to undertake future behavioural research in this environment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
4U19AI053741-06
Application #
7900783
Study Section
Special Emphasis Panel (ZAI1-EC-A (S4))
Project Start
2009-06-01
Project End
2011-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
6
Fiscal Year
2009
Total Cost
$58,828
Indirect Cost
Name
HIV-Nat, the Thai Red Cross AIDS Rch Center
Department
Type
DUNS #
671556129
City
Bangkok
State
Country
Thailand
Zip Code
10330
Paul, Robert; Apornpong, Tanakorn; Prasitsuebsai, Wasana et al. (2018) Cognition, Emotional Health, and Immunological Markers in Children With Long-Term Nonprogressive HIV. J Acquir Immune Defic Syndr 77:417-426
Paul, Robert; Prasitsuebsai, Wasana; Jahanshad, Neda et al. (2018) Structural Neuroimaging and Neuropsychologic Signatures in Children With Vertically Acquired HIV. Pediatr Infect Dis J 37:662-668
Bunupuradah, Torsak; Hansudewechakul, Rawiwan; Kosalaraksa, Pope et al. (2015) HLA-DRB1454 and predictors of new-onset asthma in HIV-infected Thai children. Clin Immunol 157:26-9
Ananworanich, Jintanat; Kerr, Stephen J; Jaimulwong, Tanyathip et al. (2015) Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children. J Virus Erad 1:196-202
Kerr, Stephen J; Puthanakit, Thanyawee; Vibol, Ung et al. (2014) Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV. AIDS Care 26:1327-35
Intasan, Jintana; Bunupuradah, Torsak; Vonthanak, Saphonn et al. (2014) Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial. AIDS Patient Care STDS 28:296-302
Puthanakit, Thanyawee; Ananworanich, Jintanat; Vonthanak, Saphonn et al. (2013) Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J 32:501-8
Bunupuradah, Torsak; Kosalaraksa, Pope; Vibol, Ung et al. (2013) Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study. AIDS Patient Care STDS 27:596-603
Puthanakit, Thanyawee; Saphonn, Vonthanak; Ananworanich, Jintanat et al. (2012) Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis 12:933-41
Haas, David W; Mootsikapun, Piroon; Ruxrungtham, Kiat et al. (2012) Clinical perspectives on human genetic screening to prevent nevirapine toxicity. Per Med 9:773-782

Showing the most recent 10 out of 16 publications